Holen Sie sich die Stockscreener-App
6.31
5.68%
-0.38
Handel nachbörslich:
6.20
-0.11
-1.74%
Schlusskurs vom Vortag:
$6.69
Offen:
$6.89
24-Stunden-Volumen:
268.66K
Relative Volume:
2.94
Marktkapitalisierung:
$262.84M
Einnahmen:
$4.71M
Nettoeinkommen (Verlust:
$-46.77M
KGV:
-3.7577
EPS:
-1.6792
Netto-Cashflow:
$-60.34M
1W Leistung:
-12.97%
1M Leistung:
-16.53%
6M Leistung:
-40.30%
1J Leistung:
-21.42%
1-Tages-Spanne:
$6.01
$6.9524
1-Wochen-Bereich:
$6.01
$8.5878
52-Wochen-Spanne:
$5.55
$11.87
Nyxoah Sa Stock (NYXH) Company Profile
Vergleichen Sie NYXH mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NYXH
Nyxoah Sa
|
6.31 | 262.84M | 4.71M | -46.77M | -60.34M | -1.6792 |
|
ISRG
Intuitive Surgical Inc
|
482.35 | 171.42B | 9.15B | 2.61B | 1.99B | 7.17 |
|
BDX
Becton Dickinson Co
|
195.96 | 55.88B | 21.39B | 1.59B | 2.55B | 5.56 |
|
ALC
Alcon Inc
|
86.48 | 42.55B | 9.93B | 1.12B | 1.58B | 2.25 |
|
RMD
Resmed Inc
|
288.28 | 41.48B | 5.15B | 1.40B | 1.65B | 9.51 |
|
WST
West Pharmaceutical Services Inc
|
246.22 | 17.25B | 2.90B | 467.20M | 306.90M | 6.37 |
Nyxoah Sa Stock (NYXH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-07-31 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-07-19 | Eingeleitet | Robert W. Baird | Neutral |
| 2022-04-21 | Eingeleitet | Oppenheimer | Outperform |
| 2022-04-06 | Eingeleitet | Wolfe Research | Peer Perform |
| 2021-12-21 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2021-07-28 | Eingeleitet | Cantor Fitzgerald | Overweight |
Alle ansehen
Nyxoah Sa Aktie (NYXH) Neueste Nachrichten
Nyxoah SA stock momentum explainedTrade Analysis Summary & Daily Profit Focused Stock Screening - Newser
Will Nyxoah SA benefit from macro trends2025 Fundamental Recap & Fast Gain Swing Trade Alerts - Newser
Nyxoah sees Q2 revenue up 73%, plans R&D shift to U.S. and Belgium; shares rise - MSN
Nyxoah wins FDA approval for Genio OSA treatment - BioWorld MedTech
Nyxoah Gains FDA Approval for Genio System, Reports 73% Revenue Increase in Q2 2025. - AInvest
Nyxoah shares rise 8.12% premarket after FDA approval for Genio system. - AInvest
What recovery options are there for Nyxoah SADaily Equity Signal Strength Summary Report - Newser
Nyxoah SA's (EBR:NYXH) market cap up €31m last week, benefiting both retail investors who own 30% as well as insiders - simplywall.st
Statistical indicators supporting Nyxoah SA’s strengthFree Low Risk Swing Trade Opportunity List - Newser
Smart tools for monitoring Nyxoah SA’s price actionPredictive Analytics for Equity Growth Potential - Newser
Stifel Maintains Nyxoah SA(NYXH.US) With Buy Rating - 富途牛牛
FDA Approves Bilateral Neurostimulator for Subset of OSA Patients - Sleep Review
Nyxoah stock surges after FDA approves Genio system for sleep apnea - Investing.com India
Nyxoah revenue jumps 73% to €1.3M in Q2 2025 - Medical Buyer
Cantor Fitzgerald reiterates Overweight rating on Nyxoah stock following FDA approval - Investing.com Nigeria
Visualizing Nyxoah SA stock with heatmapsFree Community Verified Stock Suggestions - Newser
Nyxoah reports preliminary Q2 revenue EUR 1.3M - TipRanks
Nyxoah's FDA Approval and Strategic Shifts: A High-Risk, High-Reward Play in the OSA Market? - AInvest
Real time social sentiment graph for Nyxoah SABuy Alert Based on RSI and Volume - Newser
Nyxoah SA Trading Near Value Zone — Recovery AheadMarket Surge Signal for Swing Traders Triggered - beatles.ru
Nyxoah Reports Preliminary Q2 2025 Results, FDA Approves Genio System for Moderate to Severe Sleep Apnea Patients - AInvest
FDA Approves Nyxoah's Revolutionary Sleep Apnea Device While Inspire Launches Patent Battle - Stock Titan
How Nyxoah SA stock performs during market volatilityFree Quick Gain Stock Watch With Indicators - Newser
Nyxoah Announces Preliminary Results for the Second Quarter of 2025 - Informazione.it
What are the future prospects of Nyxoah SATrade Picks with 3x Upside - thegnnews.com
Nyxoah Receives Approval from FDA for Genio® System for the Treatment of Obstructive Sleep Apnea - TradingView
FDA Approval: New Genio Sleep Apnea Device Shows 71% Success Rate in Clinical Trials - Stock Titan
When is the best time to buy Nyxoah SA stockFree Opportunity Map for Daily Stock Trading - Newser
Is Nyxoah SA forming a reversal patternHigh Reward Picks with Tight Risk Control - Newser
What drives Nyxoah SA stock priceOverwhelming financial success - Jammu Links News
Is it the right time to buy Nyxoah SA stockStay ahead with daily market updates - Jammu Links News
How does Nyxoah SA generate profit in a changing economyFree Stock Market Query - Jammu Links News
Does Nyxoah SA stock perform well during market downturnsHigh-profit stock alerts - Jammu Links News
What are the latest earnings results for Nyxoah SAFree Daily Trading Room Entry - Jammu Links News
How volatile is Nyxoah SA stock compared to the marketAchieve breakthrough performance with smart picks - Jammu Links News
What is the risk reward ratio of investing in Nyxoah SA stockFree Predictions - Jammu Links News
What markets is Nyxoah SA expanding into Is HTOOW stock a good long term investment optionExplosive returns - Jammu Links News
When is Nyxoah SA stock expected to show significant growthStrongest growth potential - Jammu Links News
Is Nyxoah SA stock overvalued or undervaluedMassive stock growth - Jammu Links News
What are Nyxoah SA company’s key revenue driversMarket-crushing profits - Jammu Links News
How strong is Nyxoah SA company’s balance sheetFree Investment Risk Control - Jammu Links News
Should I hold or sell Nyxoah SA stock in 2025Fastest-growing stock picks - Jammu Links News
Finanzdaten der Nyxoah Sa-Aktie (NYXH)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):